Yu-Yi Chu, PHD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Instructor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | National Cheng Kung University, Tainan, TW, Department of Bioscience and Biotechnology, Doctor of Philosophy PhD |
| 2011 | Kaohsiung Medical University, Kaohsiung, TW, Department of Biomedical and Environmental Biology, Bachelor of Science BS |
Postgraduate Training
| 2017-2024 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Honors & Awards
| 2023 - Present | Jesse H. Jones Endowed Fellowship Award |
| 2023 - Present | Research Award of Excellence in Sciences, The University of Texas MD Anderson Cancer Center |
| 2022 - Present | Institutional Research Highlights, The University of Texas MD Anderson Cancer Center |
| 2017 - Present | Fellowship Award, Dementia Society Taiwan |
| 2016 - Present | Ministry of Science and Technology, American Association for Cancer Research |
| 2015 - Present | Fellowship Award of EMBL Advanced Training Centre Corporate Partnership Program, EMBO/EMBL Germany |
| 2015 - Present | Ministry of Science and Technology, European Molecular Biology Laboratory EMBL Symposium: Mechanisms of Neurodegeneration |
| 2015 - Present | Outstanding University Program of National Cheng King University, European Molecular Biology Laboratory EMBL Symposium: Mechanisms of Neurodegeneration |
| 2013 - Present | Outstanding Poster Award in the International Symposium on Infectious Disease and Signal Transduction, Taiwan-Japan Joint Symposium on Cell Signaling and Gene Regulation, Taiwan |
| 2013 - Present | Thesis Competition, Institute of Bioinformatics and Biosignal Transduction, National Cheng Kung University, Taiwan |
| 2011 - Present | Award for Excellence, Poster Competition, College of Life Science, Kaohsiung Medical University, Taiwan |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Develop biomarker-guided therapeutic strategy to overcome resistance to FGFR3 inhibitors by evaluating crosstalk between MTAP and FGFR3 alterations. Invited. Gallick Lab Seminar. Houston, Texas, US.
- 2021. Targeting the ALK/CDK9-Y19 kinase cascade sensitizes tumors to PARP inhibition via destabilization of the P-TEFb complex. Invited. Research in Progress Seminar series. Houston, Texas, US.
- 2017. Astrocytic CEBPD Regulates Neuronal Viability and Spatial Learning Ability via miR-135a. Invited. Symposium of Dementia Society in Taiwan, TW.
National Presentations
- 2025. FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma. Poster. Annual AACR meeting. Chicago, Illinois, US.
- 2023. Phosphorylation of CDK9 transduces ALK signaling to promote resistance to PARP inhibitors via RNA Pol II activated homologous recombination repair. Poster. Annual AACR meeting. Orlando, Florida, US.
- 2020. Reversing acquired PARPi resistance of TNBC through combined inhibition of cMet and EGFR. Poster. San Diego, California, US.
- 2016. IL-18 induces an anti-apoptotic effect through stabilizing COX-2 mRNA expression in leukemia. Poster. New Orleans, Louisiana, US.
International Presentations
- 2015. Astrocytic CCAAT/enhancer binding protein delta regulates neuronal viability and spatial learning ability via miR-135a. Poster. European Molecular Biology Laboratory (EMBL) Symposium. Heidelberg, DE.
- 2013. CEBPD regulates Thrombospondin 1 via mir-135a in astrocytes of Alzheimer’s disease. Poster. International Symposium on Infectious Disease and Signal Transduction, TW.
Grant & Contract Support
| Date: | 2018 - 2019 |
| Title: | Targeting Receptor tyrosine kinases to overcome resistance to PARP inhibitors |
| Funding Source: | Ministry of Science and Technology in Taiwan, New Partnership Program for the Connection to the Top Labs in the World (Dragon Gate Program) |
| Role: | Co-I |
| ID: | 107-2911-1-006-519 |
| Date: | 2016 - 2017 |
| Title: | Tumor derived exosomal miRNAs regulates macrophage/microglia in glioblastoma |
| Funding Source: | Ministry of Science and Technology in Taiwan, Graduate Student Study Abroad Program |
| Role: | PI |
| ID: | 105-2917-I-006-013 |
| Date: | 2016 - 2017 |
| Title: | Transcriptional factor, CEBPD mediated immunosuppressive effects in glioblastoma |
| Funding Source: | 2016 Lee Guo-Ding scholarship, Graduate Student Study Abroad Program |
| Role: | PI |
| Date: | 2009 - 2011 |
| Title: | Developing a diagnostic ELISA assay by CHO cell secreted E2 antigen to detect swine fever virus E2 specific antibodies |
| Funding Source: | Ministry of Science and Technology in Taiwan, Undergraduate student monographic study program |
| Role: | PI |
| ID: | 99-2815-C-037-020-B |
Selected Publications
Peer-Reviewed Articles
- Chu YY. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Nat Commun, 2026. e-Pub 2026. PMID: 42115161.
- Chu YY. A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. Cancer Discov, 2026. e-Pub 2026. PMID: 42126225.
- Chu YY. CCAAT/enhancer-binding protein delta regulates miRs-4257 and 3156 to attenuate the interleukin 12 through small extracellular vesicle transmission in glioblastoma. Cancer Cell Int, 2026. e-Pub 2026. PMID: 41736026.
- Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Li CF, Bai LY, Wei Y, Lee HH, Yang R, Yao J, Wang H, Wang YN, Chang WC, Shen YC, Wang SC, Chou CW, Fu J, Ling J, Chu YY, Chiu CF, Wang M, Yu D, Chiao PJ, Liang H, Maitra A, Ying H, Hung MC. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer. bioRxiv, 2024. e-Pub 2024. PMID: 39484589.
- Nie L, Wang YN, Hsu JM, Hou J, Chu YY, Chan LC, Huo L, Wei Y, Deng R, Tang J, Hsu YH, Ko HW, Lim SO, Huang K, Chen MK, Chiu TJ, Cheng CC, Fang YF, Li CW, Goverdhan A, Wu HJ, Lee CC, Wang WL, Hsu J, Chiao P, Wang SC, Hung MC. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am J Cancer Res 13(4):1209-1239, 2023. e-Pub 2023. PMID: 37168336.
- Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
- Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, Liu C, Hsu JL, Chang WC, Yang R, Chan LC, Qu J, Zhang S, Ying H, Yu D, Hung MC. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Res 82(11):2185-2195, 2022. e-Pub 2022. PMID: 35385574.
- Yang R, Sun L, Li CF, Wang YH, Xia W, Liu B, Chu YY, Bover L, Vien L, Hung MC. Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death. J Biol Chem 298(4):101821, 2022. e-Pub 2022. PMID: 35283189.
- Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, Yang WH, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng LB, Hung MC. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem 298(4):101817, 2022. e-Pub 2022. PMID: 35278434.
- Wang YN, Lee HH, Wei Y, Chu YY, Xia W, Wang M, Yu D, Hung MC. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc 3(1):101198, 2022. e-Pub 2022. PMID: 35243381.
- Gao Y, Chen MK, Chu YY, Yang L, Yu D, Liu Y, Hung MC. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. Am J Cancer Res 11(1):236-250, 2021. e-Pub 2021. PMID: 33520371.
- Han Y, Wei Y, Yao J, Chu YY, Li CW, Hsu JL, Nie L, Hung MC. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERalpha expression in high-grade serous ovarian carcinoma. Am J Cancer Res 10(4):1194-1206, 2020. e-Pub 2020. PMID: 32368395.
- Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
- Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun 10(1):5114, 2019. e-Pub 2019. PMID: 31704972.
- Dong Q, Du Y, Li H, Liu C, Wei Y, Chen MK, Zhao X, Chu YY, Qiu Y, Qin L, Yamaguchi H, Hung MC. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res 79(4):819-829, 2019. e-Pub 2019. PMID: 30573522.
- Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res 9(3):608-618, 2019. e-Pub 2019. PMID: 30949414.
- Chu YY, Ko CY, Wang SM, Lin PI, Wang HY, Lin WC, Wu DY, Wang LH, Wang JM. Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia. Cell Death Dis 8(11):e3167, 2017. e-Pub 2017. PMID: 29120412.
- Wang WJ, Li CF, Chu YY, Wang YH, Hour TC, Yen CJ, Chang WC, Wang JM. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. Clin Cancer Res 23(2):503-513, 2017. e-Pub 2017. PMID: 27435393.
- Cheng YL, Lin YS, Chen CL, Tsai TT, Tsai CC, Wu YW, Ou YD, Chu YY, Wang JM, Yu CY, Lin CF. Activation of Nrf2 by the dengue virus causes an increase in CLEC5A, which enhances TNF-alpha production by mononuclear phagocytes. Sci Rep 6:32000, 2016. e-Pub 2016. PMID: 27561946.
- Chu YY, Ko CY, Wang WJ, Wang SM, Gean PW, Kuo YM, Wang JM. Astrocytic CCAAT/Enhancer Binding Protein delta Regulates Neuronal Viability and Spatial Learning Ability via miR-135a. Mol Neurobiol 53(6):4173-4188, 2016. e-Pub 2016. PMID: 26208701.
- Ko CY, Wang WL, Li CF, Jeng YM, Chu YY, Wang HY, Tseng JT, Wang JM. IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia. J Leukoc Biol 99(1):131-41, 2016. e-Pub 2016. PMID: 26342105.
- Cheng TC, Pan CH, Chen CS, Chuang KH, Chuang CH, Huang CC, Chu YY, Yang YC, Chu PY, Kao CH, Hsieh YC, Cheng TL. Direct coating of culture medium from cells secreting classical swine fever virus E2 antigen on ELISA plates for detection of E2-specific antibodies. Vet J 205(1):107-9, 2015. e-Pub 2015. PMID: 25975854.
- Ko CY, Chu YY, Narumiya S, Chi JY, Furuyashiki T, Aoki T, Wang SM, Chang WC, Wang JM. CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer's disease. Neurobiol Aging 36(3):1356-68, 2015. e-Pub 2015. PMID: 25554493.
- Ko CY, Wang WL, Wang SM, Chu YY, Chang WC, Wang JM. Glycogen synthase kinase-3beta-mediated CCAAT/enhancer-binding protein delta phosphorylation in astrocytes promotes migration and activation of microglia/macrophages. Neurobiol Aging 35(1):24-34, 2014. e-Pub 2014. PMID: 23993701.
Review Articles
- Chu YY, Yam C, Yamaguchi H, Hung MC. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. J Biomed Sci 29(1):86, 2022. e-Pub 2022. PMID: 36284291.
Other Articles
- Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun 11(1):673, 2020. PMID: 31996688.
Abstracts
- Chu YY. FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma. Annual AACR meeting, 2025.
Patents
- Hung MC, Chen MK, Chu YY. Combinatorial therapy targeting parp1 and rtk. Patent Number: 17/617,923.
Patient Reviews
CV information above last modified August 11, 2026